Stevens Capital Closes Out Position in Eli Lilly

Company Overview - Eli Lilly and Company is a leading global pharmaceutical firm with a market capitalization of $605.19 billion as of August 12, 2025, focusing on research-driven innovation and strategic alliances to maintain a competitive position [5] - The company offers a broad portfolio of pharmaceuticals for various therapeutic areas, including diabetes, oncology, immunology, and neuroscience, with key products such as Humalog, Trulicity, Verzenio, and Taltz [8] - Eli Lilly generates revenue primarily through the development, manufacturing, and global sale of branded prescription drugs, targeting patients with chronic and acute medical conditions across more than 120 countries [8] Financial Performance - As of the quarter ended June 30, 2025, Eli Lilly's revenue (TTM) was $53.26 billion, with a net income (TTM) of $13.80 billion [3] - The company's dividend yield stands at 0.79%, with a forward P/E ratio of 32.15 and an EV/EBITDA of 35.32 [2][3] - Eli Lilly's one-year total return was -23.1%, underperforming the S&P 500 by 38.3 percentage points [2] Market Position and Competition - Eli Lilly's weight loss drug, Zepbound, claims to provide 47% greater relative weight loss compared to Novo Nordisk's Wegovy, positioning it favorably in the competitive weight-loss drug market [9] - The race to launch oral versions of weight loss drugs is intensifying, with Novo Nordisk's oral Wegovy under FDA review and Eli Lilly planning to submit its oral weight loss drug, orforglipron, for approval by the end of 2025 [10][11] - In clinical trials, Novo Nordisk's oral Wegovy achieved a mean weight loss of 15.1%, while orforglipron reached 12.4% at its highest dosage, indicating potential challenges for Eli Lilly in maintaining its competitive edge [11]